Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

1.

Antiangiogenesis to curb urothelial cancer.

Lancet.
Bellmunt J.
| Sep 12, 2017
2.

Transformational thinking about asthma.

Lancet.
Camargo CA.
| Sep 11, 2017
3.

Advances in paediatric urology.

Lancet.
Diamond DA, Chan IHY, Holland AJA, Kurtz MP, Nelson C, Estrada CR, Bauer S, Tam PKH.
| Sep 09, 2017
4.

Long-term implications and global impact of paediatric surgery.

Lancet.
Tam PKH, Davenport M, Chan IHY, Numanoglu A, Hoebeke P, Diamond DA.
| Sep 09, 2017
5.

What does endotyping mean for treatment in chronic obstructive pulmonary disease?

Lancet.
Agustí A, Celli B, Faner R.
| Sep 02, 2017
6.

Prevention of hearing loss in patients with multidrug-resistant tuberculosis.

Lancet.
Cox H, Reuter A, Furin J, Seddon J.
| Sep 02, 2017
7.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Lancet.
Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.
| Aug 31, 2017
8.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Lancet.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS.
| Aug 25, 2017
10.

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.

Lancet.
Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R.
| Aug 26, 2017
11.

Update on antithrombotic therapy after percutaneous coronary revascularisation.

Lancet.
Cuisset T, Verheugt FWA, Mauri L.
| Aug 19, 2017
12.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Lancet.
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.
| Jul 27, 2017
13.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Lancet.
Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A.
| Jul 26, 2017
14.

Ethical considerations in noise-induced hearing loss research.

Lancet.
Maison SF, Rauch SD.
| Sep 02, 2017
15.

Body-mass index and all-cause mortality - Authors' reply.

Lancet.
Di Angelantonio E, Bhupathiraju SN, Hu FB, Danesh J, Peto R, Lewington S.
| 06 10, 2017
16.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Lancet.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M, Trotman J.
| Aug 05, 2017
17.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

Lancet.
Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.
| 07 15, 2017
18.

Warnings, uncertainty, and clinical practice.

Lancet.
Polaner DM, Zuk J, McCann ME, Davidson A.
| Jun 03, 2017
19.

Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.

Lancet.
Avidan MS, Maybrier HR, Abdallah AB, Jacobsohn E, Vlisides PE, Pryor KO, Veselis RA, Grocott HP, Emmert DA, Rogers EM, Downey RJ, Yulico H, Noh GJ, Lee YH, Waszynski CM, Arya VK, Pagel PS, Hudetz JA, Muench MR, Fritz BA, Waberski W, Inouye SK, Mashour GA, Apakama GP.
| 07 15, 2017
20.

STREAM characterisation correction - Authors' reply.

Lancet.
Reed GW, Cannon CP.
| May 27, 2017